Nicola Frego, Francesco Barletta, Mario de Angelis, Stefano Resca, Enrico Vecchio, Sara Tamburini, Alessandro Pissavini, Andrea Noya Mourullo, Claudio Brancelli, Edward Lambert, Frederick D'Hondt, Ruben De Groote, Giorgio Gandaglia, Geert De Naeyer, Alberto Briganti, Francesco Montorsi, Alexandre Mottrie
{"title":"高危前列腺癌患者神经血管束的保存:来自两个高容量三级中心的长期肿瘤预后","authors":"Nicola Frego, Francesco Barletta, Mario de Angelis, Stefano Resca, Enrico Vecchio, Sara Tamburini, Alessandro Pissavini, Andrea Noya Mourullo, Claudio Brancelli, Edward Lambert, Frederick D'Hondt, Ruben De Groote, Giorgio Gandaglia, Geert De Naeyer, Alberto Briganti, Francesco Montorsi, Alexandre Mottrie","doi":"10.1016/j.euf.2025.04.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Preservation of neurovascular bundles (NVBs) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) has been associated with better functional outcomes. The aim of this study is to investigate the oncological impact of NVB preservation in patients with high-risk PCa.</p><p><strong>Methods: </strong>D'Amico high-risk PCa patients who underwent RP between 2002 and 2022 at two high-volume referral centers were included in the study analysis. Patients who underwent neoadjuvant and adjuvant therapy as well as those with evidence of M1 or pT4 disease were excluded. Propensity score and inverse probability of treatment weighting were used to account for a selection bias in treatment allocation. A time-to-event analysis was performed to assess the effect of NVB preservation on biochemical (BCR) and clinical (CR) recurrences.</p><p><strong>Key findings and limitations: </strong>Overall, 1551 high-risk PCa patients were included in the analysis (56.8% and 43.2% underwent preservation of NVBs vs no NVBs). After applying the inverse probability of treatment weighting, at 120 mo after RP, BCR- and CR-free survival rates were 27.1% versus 27.5% and 58.9% versus 58.4% for the preservation of NVBs versus no NVBs, respectively. In the models adjusted for pathological characteristics, age, and prostate-specific antigen density, NVB preservation was not associated with a significantly higher risk of BCR (adjusted hazard ratio [aHR]: 0.79, 95% confidence interval [CI]: 0.56-1.11, p = 0.2) and CR (aHR: 0.78, 95% CI: 0.45-1.32, p = 0.4), compared with no NVB preservation. In the subgroup analysis of pathological International Society of Urological Pathology grade 4-5 and/or pT stage 3a-3b patients, NVB preservation did not make oncological outcomes worse at both univariable and multivariable cox analyses.</p><p><strong>Conclusions and clinical implications: </strong>NVB preservation might have a limited effect on the risk of BCR and CR compared with no preservation. Nerve-sparing surgery may be attempted in selected high-risk PCa patients without compromising long-term oncological outcome.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preservation of Neurovascular Bundles in High-risk Prostate Cancer Patients: Long-term Oncological Outcomes from Two High-volume Tertiary Centers.\",\"authors\":\"Nicola Frego, Francesco Barletta, Mario de Angelis, Stefano Resca, Enrico Vecchio, Sara Tamburini, Alessandro Pissavini, Andrea Noya Mourullo, Claudio Brancelli, Edward Lambert, Frederick D'Hondt, Ruben De Groote, Giorgio Gandaglia, Geert De Naeyer, Alberto Briganti, Francesco Montorsi, Alexandre Mottrie\",\"doi\":\"10.1016/j.euf.2025.04.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Preservation of neurovascular bundles (NVBs) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) has been associated with better functional outcomes. The aim of this study is to investigate the oncological impact of NVB preservation in patients with high-risk PCa.</p><p><strong>Methods: </strong>D'Amico high-risk PCa patients who underwent RP between 2002 and 2022 at two high-volume referral centers were included in the study analysis. Patients who underwent neoadjuvant and adjuvant therapy as well as those with evidence of M1 or pT4 disease were excluded. Propensity score and inverse probability of treatment weighting were used to account for a selection bias in treatment allocation. A time-to-event analysis was performed to assess the effect of NVB preservation on biochemical (BCR) and clinical (CR) recurrences.</p><p><strong>Key findings and limitations: </strong>Overall, 1551 high-risk PCa patients were included in the analysis (56.8% and 43.2% underwent preservation of NVBs vs no NVBs). After applying the inverse probability of treatment weighting, at 120 mo after RP, BCR- and CR-free survival rates were 27.1% versus 27.5% and 58.9% versus 58.4% for the preservation of NVBs versus no NVBs, respectively. In the models adjusted for pathological characteristics, age, and prostate-specific antigen density, NVB preservation was not associated with a significantly higher risk of BCR (adjusted hazard ratio [aHR]: 0.79, 95% confidence interval [CI]: 0.56-1.11, p = 0.2) and CR (aHR: 0.78, 95% CI: 0.45-1.32, p = 0.4), compared with no NVB preservation. In the subgroup analysis of pathological International Society of Urological Pathology grade 4-5 and/or pT stage 3a-3b patients, NVB preservation did not make oncological outcomes worse at both univariable and multivariable cox analyses.</p><p><strong>Conclusions and clinical implications: </strong>NVB preservation might have a limited effect on the risk of BCR and CR compared with no preservation. Nerve-sparing surgery may be attempted in selected high-risk PCa patients without compromising long-term oncological outcome.</p>\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2025.04.015\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2025.04.015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:行根治性前列腺切除术(RP)的前列腺癌(PCa)患者保存神经血管束(NVBs)与更好的功能预后相关。本研究的目的是探讨NVB保留对高危前列腺癌患者的肿瘤学影响。方法:研究分析纳入了2002年至2022年间在两个大容量转诊中心接受RP的D'Amico高危PCa患者。接受新辅助和辅助治疗的患者以及有M1或pT4疾病证据的患者被排除在外。倾向得分和治疗加权逆概率用于解释治疗分配中的选择偏差。通过时间-事件分析来评估NVB保存对生化(BCR)和临床(CR)复发的影响。主要发现和局限性:总体而言,1551例高风险PCa患者被纳入分析(56.8%和43.2%的患者接受了NVBs保存,而没有接受NVBs)。在应用治疗加权逆概率后,RP后120个月,保留NVBs和无NVBs的BCR和无cr生存率分别为27.1%对27.5%和58.9%对58.4%。在对病理特征、年龄和前列腺特异性抗原密度进行校正的模型中,与未保存NVB相比,保存NVB与BCR(校正风险比[aHR]: 0.79, 95%可信区间[CI]: 0.56-1.11, p = 0.2)和CR (aHR: 0.78, 95% CI: 0.45-1.32, p = 0.4)的风险没有显著升高。在国际泌尿病理学会病理分级4-5和/或pT期3a-3b患者的亚组分析中,在单变量和多变量cox分析中,NVB保存并未使肿瘤预后恶化。结论和临床意义:与不保存相比,保存NVB对BCR和CR的风险影响有限。在不影响长期肿瘤预后的情况下,可以选择高危PCa患者进行神经保留手术。
Preservation of Neurovascular Bundles in High-risk Prostate Cancer Patients: Long-term Oncological Outcomes from Two High-volume Tertiary Centers.
Background and objective: Preservation of neurovascular bundles (NVBs) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) has been associated with better functional outcomes. The aim of this study is to investigate the oncological impact of NVB preservation in patients with high-risk PCa.
Methods: D'Amico high-risk PCa patients who underwent RP between 2002 and 2022 at two high-volume referral centers were included in the study analysis. Patients who underwent neoadjuvant and adjuvant therapy as well as those with evidence of M1 or pT4 disease were excluded. Propensity score and inverse probability of treatment weighting were used to account for a selection bias in treatment allocation. A time-to-event analysis was performed to assess the effect of NVB preservation on biochemical (BCR) and clinical (CR) recurrences.
Key findings and limitations: Overall, 1551 high-risk PCa patients were included in the analysis (56.8% and 43.2% underwent preservation of NVBs vs no NVBs). After applying the inverse probability of treatment weighting, at 120 mo after RP, BCR- and CR-free survival rates were 27.1% versus 27.5% and 58.9% versus 58.4% for the preservation of NVBs versus no NVBs, respectively. In the models adjusted for pathological characteristics, age, and prostate-specific antigen density, NVB preservation was not associated with a significantly higher risk of BCR (adjusted hazard ratio [aHR]: 0.79, 95% confidence interval [CI]: 0.56-1.11, p = 0.2) and CR (aHR: 0.78, 95% CI: 0.45-1.32, p = 0.4), compared with no NVB preservation. In the subgroup analysis of pathological International Society of Urological Pathology grade 4-5 and/or pT stage 3a-3b patients, NVB preservation did not make oncological outcomes worse at both univariable and multivariable cox analyses.
Conclusions and clinical implications: NVB preservation might have a limited effect on the risk of BCR and CR compared with no preservation. Nerve-sparing surgery may be attempted in selected high-risk PCa patients without compromising long-term oncological outcome.
期刊介绍:
European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU).
EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.